ONCIMMUNE: ECLS lung cancer study using EarlyCDT®-Lung meets primary endpoint | CORPORATE | 168p vs. 143p
ONCIMMUNE - CORPORATE | 168p vs. 143pECLS lung cancer study using EarlyCDT®-Lung meets primary endpoint
ONC’s EarlyCDT-Lung blood test effective in landmark lung study
Detailed results in a leading medical publication in Q3 2019
Up to 200,000 patients to be tested using EarlyCDT
A long-time in the making but worth the wait
We upgrade our FV to 168p.
Oncimmune Holdings and its subsidiaries are engaged in cancer diagnosis.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.